Treatment of Adrenocorticotropin-Dependent Cushing’s Syndrome: A Consensus Statement
Open accessThe DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Our objective was to evaluate the published literature and reach a consensus on the treatment of patients with ACTH-dependent Cushing's syndrome, because there is no recent consensus on the management of this rare disorder. PARTICIPANTS: Thirty-two leading endocrinologists, clinicians, and neurosurgeons with specific expertise in the management of ACTH-dependent Cushing's syndrome representing nine countries were chosen to address 1) criteria for cure and remission of this disorder, 2) surgical treatment of Cushing's disease, 3) therapeutic options in the event of persistent disease after transsphenoidal surgery, 4) medical therapy of Cushing's disease, and 5) management of ectopic ACTH syndrome, Nelson's syndrome, and special patient populations. EVIDENCE: Participants presented published scientific data, which formed the basis of the recommendations. Opinion shared by a majority of experts was used where strong evidence was lacking. CONSENSUS PROCESS: Participants met for 2 d, during which there were four chaired sessions of presentations, followed by general discussion where a consensus was reached. The consensus statement was prepared by a steering committee and was then reviewed by all authors, with suggestions incorporated if agreed upon by the majority. CONCLUSIONS: ACTH-dependent Cushing's syndrome is a heterogeneous disorder requiring a multidisciplinary and individualized approach to patient management. Generally, the treatment of choice for ACTH-dependent Cushing's syndrome is curative surgery with selective pituitary or ectopic corticotroph tumor resection. Second-line treatments include more radical surgery, radiation therapy (for Cushing's disease), medical therapy, and bilateral adrenalectomy. Because of the significant morbidity of Cushing's syndrome, early diagnosis and prompt therapy are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As with Cushing’s disease, it may be helpful to use a cortisol synthesis blocking drug while waiting for definitive treatment (18) and in cases where definitive treatment is not possible.”
From ACTH Antagonists (2016) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Once a diagnosis is conclusively made, the optimal treatment is surgical removal of the tumor – ideally preserving the remaining pituitary function.”
From ACTH Antagonists (2016) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362 · cited 3×
“excess cortisol secretion by unilateral adrenocortical tumors or by bilateral adrenal hyperplasia or dysplasia (1).”
BackgroundInfluentialSelf-citationValvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884 · cited 1×
“However, more data are required not only for efficacy but also to address the long-term safety of cabergoline in these patients (84, 85).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationDopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
Ilias, I., Torpy, D. J., Pacak, K., Mullen, N., Wesley, R. A., & Nieman, L. K. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2527 · Cited by 713
Self-citationBruns, C., Lewis, I., Briner, U., Meno-Tetang, G., & Weckbecker, G. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460707 · Cited by 692
Isidori, A. M., Kaltsas, G. A., Pozza, C., Frajese, V., Newell-Price, J., Reznek, R. H., Jenkins, P. J., Monson, J. P., Grossman, A. B., & Besser, G. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1542 · Cited by 522
Self-citationThe hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment
Lindsay, J. R., & Nieman, L. K. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0025 · Cited by 449 · cited 1×
“Detection of Cushing’s syndrome usually occurs late in gestation, and the diagnosis is complicated by the signs of normal pregnancy, such as central weight gain, facial plethora, and pigmentation (101) and the normal physiological changes in the maternal HPA axis.”
BackgroundSelf-citationPosterior retroperitoneoscopic adrenalectomy–results of 560 procedures in 520 patients
Walz, M. K., Alesina, P. F., Wenger, F. A., Deligiannis, A., Szuczik, E., Petersenn, S., Ommer, A., Groeben, H., Peitgen, K., Janssen, O. E., et al. (2006) · Surgery · doi:10.1016/j.surg.2006.07.039 · Cited by 425
Self-citationRisk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma.
Brada, M., Ford, D., Ashley, S., Bliss, J. M., Crowley, S., Mason, M., Rajan, B., & Traish, D. (1992) · BMJ · doi:10.1136/bmj.304.6838.1343 · Cited by 413 · cited 1×
“The risk of second tumor formation after pituitary radiation is considered to be in the range of 1–2% (39), but this may not be due to the radiotherapy per se.”
Background
Research works printed but not linked: 1
- 52. Sonino N, Boscaro M, Ambroso G, Merola G, Mantero F 1986 Prolonged - treatment of Cushing's disease with metyrapone and aminoglutethimide. IRCS Med Sci 14:485-486
Cited by
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Self-citationConsensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953
“6,7 140 Patients in remission require glucocorticoid replacement until HPA axis recovery.”
Self-citationComplications of Cushing's syndrome: state of the art
Pivonello, R., Isidori, A. M., De Martino, M. C., Newell-Price, J., Biller, B. M. K., & Colao, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00086-3 · Cited by 641
Self-citationA 12-month phase 3 study of pasireotide in Cushing's disease
Colao, A., Petersenn, S., Newell-Price, J., Findling, J. W., Gu, F., Maldonado, M., Schoenherr, U., Dipl.-Biol., Mills, D., Salgado, L. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105743 · Cited by 628
“Asthenia 2 (2) 13 (16) 2 (2) 5 (6) 4 (2) 18 (11)”
Self-citationMicko, A. S. G., Wöhrer, A., Wolfsberger, S., & Knosp, E. (2015) · Journal of Neurosurgery · doi:10.3171/2014.12.jns141083 · Cited by 577
“We used the most recent consensus statements 5,6, 25,53 to define ER.”
MethodThe Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
Self-citationFleseriu, M., Biller, B. M. K., Findling, J. W., Molitch, M. E., Schteingart, D. E., Gross, C., on behalf of the SEISMIC Study Investigators, The SEISMIC Study Investigators include, Auchus, R., Bailey, T., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3350 · Cited by 479
“Regardless of cause, surgery is usually the treatment of choice; however, complete removal of the neoplasm may not be possible (4, 5).”
BackgroundSelf-citationValassi, E., Santos, A., Yaneva, M., Tóth, M., Strasburger, C. J., Chanson, P., Wass, J. A. H., Chabre, O., Pfeifer, M., Feelders, R. A., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0272 · Cited by 402
Self-citationMortality in Patients with Pituitary Disease
Sherlock, M., Ayuk, J., Tomlinson, J. W., Toogood, A. A., Aragon-Alonso, A., Sheppard, M. C., Bates, A. S., & Stewart, P. M. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0033 · Cited by 392
“As outlined in recent clinical guidelines statements, further outcome studies are urgently required to inform an evidence base for treatingpatientswithCushing’sdisease,particularly when hypercortisolism and/or clinical symptoms/signs are mild (208).”
BackgroundSelf-citationRecurrent gain-of-function USP8 mutations in Cushing's disease
Ma, Z.-Y., Song, Z.-J., Chen, J.-H., Wang, Y.-F., Li, S.-Q., Zhou, L.-F., Mao, Y., Li, Y.-M., Hu, R.-G., Zhang, Z.-Y., et al. (2015) · Cell Research · doi:10.1038/cr.2015.20 · Cited by 368
Pivonello, R., De Martino, M. C., Cappabianca, P., De Leo, M., Faggiano, A., Lombardi, G., Hofland, L. J., Lamberts, S. W. J., & Colao, A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1533 · Cited by 328
Self-citationKetoconazole in Cushing's disease: is it worth a try?
Castinetti, F., Guignat, L., Giraud, P., Muller, M., Kamenicky, P., Drui, D., Caron, P., Luca, F., Donadille, B., Vantyghem, M. C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3628 · Cited by 285
Self-citationBoscaro, M., Ludlam, W. H., Atkinson, B., Glusman, J. E., Petersenn, S., Reincke, M., Snyder, P., Tabarin, A., Biller, B. M. K., Findling, J., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1008 · Cited by 279
Self-citationFeelders, R. A., Pulgar, S. J., Kempel, A., & Pereira, A. M. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-1095 · Cited by 256
Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors
Goh, G., Scholl, U. I., Healy, J. M., Choi, M., Prasad, M. L., Nelson-Williams, C., Kunstman, J. W., Korah, R., Suttorp, A.-C., Dietrich, D., et al. (2014) · Nature Genetics · doi:10.1038/ng.2956 · Cited by 251
Günther, T., Tulipano, G., Dournaud, P., Bousquet, C., Csaba, Z., Kreienkamp, H.-J., Lupp, A., Korbonits, M., Castaño, J. P., Wester, H.-J., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015388 · Cited by 253
“Pituitary-dependent Cushing disease is caused by a corticotroph cell adenoma hypersecreting ACTH thus leading to adrenal cortisol overproduction (Biller et al., 2008).”
BackgroundSelf-citationEGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas
Fukuoka, H., Cooper, O., Ben-Shlomo, A., Mamelak, A., Ren, S.-G., Bruyette, D., & Melmed, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci60417 · Cited by 254
Self-citationBertagna, X., Guignat, L., Groussin, L., & Bertherat, J. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.06.001 · Cited by 222
Self-citationAlexandraki, K. I., & Grossman, A. B. (2010) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-010-9139-z · Cited by 211
“Hence, after the completion of biochemical diagnostic work-up or during the ‘waiting follow-up period’ until the identification of a covert or occult tumour, medical treatment has a central role [13, 63 ].”
BackgroundSelf-citationKamenický, P., Droumaguet, C., Salenave, S., Blanchard, A., Jublanc, C., Gautier, J.-F., Brailly-Tabard, S., Leboulleux, S., Schlumberger, M., Baudin, E., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0536 · Cited by 221
Pivonello, R., Fleseriu, M., Newell-Price, J., Bertagna, X., Findling, J., Shimatsu, A., Gu, F., Auchus, R., Leelawattana, R., Lee, E. J., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30240-0 · Cited by 222
Self-citationHypercoagulable State in Cushing’s Syndrome: A Systematic Review
Van Zaane, B., Nur, E., Squizzato, A., Dekkers, O. M., Twickler, M. (. B., Fliers, E., Gerdes, V. E. A., Büller, H. R., & Brandjes, D. P. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0290 · Cited by 216
Cushing's disease: pathobiology, diagnosis, and management
Lonser, R. R., Nieman, L., & Oldfield, E. H. (2017) · Journal of Neurosurgery · doi:10.3171/2016.1.jns152119 · Cited by 215
Self-citationTritos, N. A., Biller, B. M. K., & Swearingen, B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.12 · Cited by 208
Self-citationClinical and Organizational Factors in the Initial Evaluation of Patients With Lung Cancer
Ost, D. E., Jim Yeung, S.-C., Tanoue, L. T., & Gould, M. K. (2013) · Chest · doi:10.1378/chest.12-2352 · Cited by 195
Incidence of Venous Thromboembolism in Patients with Cushing's Syndrome: A Multicenter Cohort Study
Stuijver, D. J. F., van Zaane, B., Feelders, R. A., Debeij, J., Cannegieter, S. C., Hermus, A. R., van den Berg, G., Pereira, A. M., de Herder, W. W., Wagenmakers, M. A. E. M., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1661 · Cited by 208
“Although low-dose heparin has been advised in the immediate perioperative period of CS (14), to date, specific guidelines on the treatment of CS and on the prevention of thrombosis have not been developed (15, 16).”
BackgroundSelf-citationAlexandraki, K. I., Kaltsas, G. A., Isidori, A. M., Storr, H. L., Afshar, F., Sabin, I., Akker, S. A., Chew, S. L., Drake, W. M., Monson, J. P., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0921 · Cited by 203
Self-citationCabergoline monotherapy in the long-term treatment of Cushing's disease
Godbout, A., Manavela, M., Danilowicz, K., Beauregard, H., Bruno, O. D., & Lacroix, A. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0382 · Cited by 202
Self-citationOutcome of Bilateral Adrenalectomy in Cushing's Syndrome: A Systematic Review
Ritzel, K., Beuschlein, F., Mickisch, A., Osswald, A., Schneider, H. J., Schopohl, J., & Reincke, M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1470 · Cited by 201
TASK channel deletion in mice causes primary hyperaldosteronism
Davies, L. A., Hu, C., Guagliardo, N. A., Sen, N., Chen, X., Talley, E. M., Carey, R. M., Bayliss, D. A., & Barrett, P. Q. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712000105 · Cited by 198
Diabetes in Cushing syndrome: basic and clinical aspects
Mazziotti, G., Gazzaruso, C., & Giustina, A. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.09.001 · Cited by 193
Bertagna, X., Pivonello, R., Fleseriu, M., Zhang, Y., Robinson, P., Taylor, A., Watson, C. E., Maldonado, M., Hamrahian, A. H., Boscaro, M., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2117 · Cited by 189
Self-citationPituitary adenomas: an overview.
Lake, M. G., Krook, L. S., & Cruz, S. V. (2013) · PubMed · Cited by 193
Pregnancy and pituitary disorders
Karaca, Z., Tanriverdi, F., Unluhizarci, K., & Kelestimur, F. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0923 · Cited by 191
Long-Term Results of Stereotactic Radiosurgery in Secretory Pituitary Adenomas
Castinetti, F., Nagai, M., Morange, I., Dufour, H., Caron, P., Chanson, P., Cortet-Rudelli, C., Kuhn, J.-M., Conte-Devolx, B., Regis, J., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2772 · Cited by 187
Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center
Baudry, C., Coste, J., Bou Khalil, R., Silvera, S., Guignat, L., Guibourdenche, J., Abbas, H., Legmann, P., Bertagna, X., & Bertherat, J. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0358 · Cited by 187
Self-citationPreda, V. A., Sen, J., Karavitaki, N., & Grossman, A. B. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0274 · Cited by 172
Self-citation60 YEARS OF POMC: Biosynthesis, trafficking, and secretion of pro-opiomelanocortin-derived peptides
Cawley, N. X., Li, Z., & Loh, Y. P. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-15-0323 · Cited by 167
“Another example is Nelson’s syndrome, which results from a rapid enlargement of a preexisting ACTH-secreting pituitary adenoma that occurs after the removal of the adrenal glands, thus lacking the negative feedback of cortisol on the production of ACTH (Biller et al. 2008).”
Identification of recurrent USP48 and BRAF mutations in Cushing’s disease
Chen, J., Jian, X., Deng, S., Ma, Z., Shou, X., Shen, Y., Zhang, Q., Song, Z., Li, Z., Peng, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05275-5 · Cited by 174
Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment
van der Pas, R., Leebeek, F. W. G., Hofland, L. J., de Herder, W. W., & Feelders, R. A. (2013) · Clinical Endocrinology · doi:10.1111/cen.12094 · Cited by 162
Self-citationDelayed Remission after Transsphenoidal Surgery in Patients with Cushing’s Disease
Valassi, E., Biller, B. M. K., Swearingen, B., Pecori Giraldi, F., Losa, M., Mortini, P., Hayden, D., Cavagnini, F., & Klibanski, A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1672 · Cited by 160
Self-citationPetersenn, S., Beckers, A., Ferone, D., van der Lely, A., Bollerslev, J., Boscaro, M., Brue, T., Bruzzi, P., Casanueva, F. F., Chanson, P., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0883 · Cited by 156
Self-citationMerits and pitfalls of mifepristone in Cushing's syndrome
Castinetti, F., Fassnacht, M., Johanssen, S., Terzolo, M., Bouchard, P., Chanson, P., Do Cao, C., Morange, I., Picó, A., Ouzounian, S., et al. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0098 · Cited by 163
Fleseriu, M., Pivonello, R., Young, J., Hamrahian, A. H., Molitch, M. E., Shimizu, C., Tanaka, T., Shimatsu, A., White, T., Hilliard, A., et al. (2016) · Pituitary · doi:10.1007/s11102-015-0692-z · Cited by 155
Self-citationSomatostatin receptor ligands and resistance to treatment in pituitary adenomas
Ramos, D. C., & Fleseriu, M. (2014) · Journal of Molecular Endocrinology · doi:10.1530/jme-14-0011 · Cited by 167
“2 mg/dl (w50 nmol/l) are associated with remission (Biller et al. 2008, Hameed et al. 2013), but delayed remission has also been noted.”
BackgroundVilar, L., Naves, L. A., Azevedo, M. F., Arruda, M. J., Arahata, C. M., Silva, L. M. E., Agra, R., Pontes, L., Montenegro, L., Albuquerque, J. L., et al. (2009) · Pituitary · doi:10.1007/s11102-009-0209-8 · Cited by 154
“their limited efficacy, they never reached a widespread clinical use for the treatment of CD [ 4 , 8, 10].”
BackgroundInfluentialColao, A., De Block, C., Gaztambide, M. S., Kumar, S., Seufert, J., & Casanueva, F. F. (2014) · Pituitary · doi:10.1007/s11102-013-0483-3 · Cited by 151
“Although initial surgery is most frequently used as the first-line option, it often fails [1, 17].”
BackgroundSelf-citationEndoscopic Transsphenoidal Pituitary Surgery: Evidence of an Operative Learning Curve
Leach, P. A., Abou-Zeid, A. H., Kearney, T., Davis, J. R., Trainer, P. J., & Gnanalingham, K. K. (2010) · Neurosurgery · doi:10.1227/neu.0b013e3181ef25c5 · Cited by 149
Medical Treatment of Cushing's Disease
Feelders, R. A., & Hofland, L. J. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3126 · Cited by 143
Self-citationSelective Progesterone Receptor Modulators—Mechanisms and Therapeutic Utility
Islam, M. S., Afrin, S., Jones, S. I., & Segars, J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa012 · Cited by 143
Translocator protein-mediated pharmacology of cholesterol transport and steroidogenesis
Papadopoulos, V., Aghazadeh, Y., Fan, J., Campioli, E., Zirkin, B., & Midzak, A. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.03.014 · Cited by 127
“Compounds targeting TSPO’s CRAC motif may thus serve as pharmacological leads for the treatment of diseases of steroidal excess, such as Cushing’s disease in humans and animals (Biller et al., 2008), as well as a variety of endocrine tumors (Freeman, 1986).”
BackgroundGlucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management
Scaroni, C., Zilio, M., Foti, M., & Boscaro, M. (2017) · Endocrine Reviews · doi:10.1210/er.2016-1105 · Cited by 140
Self-citationLiu, N., Jiang, H., Ben-Shlomo, A., Wawrowsky, K., Fan, X., Lin, S., & Melmed, S. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018091108 · Cited by 140
“Although transsphenoidal ACTH-secreting tumor resection yields 30% to 70% surgical cure rates, adenoma recurrence rate is high (2).”
BackgroundSelf-citationManetti, L., Bogazzi, F., Giovannetti, C., Raffaelli, V., Genovesi, M., Pellegrini, G., Ruocco, L., Iannelli, A., & Martino, E. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0583 · Cited by 138
Hofstetter, C. P., Nanaszko, M. J., Mubita, L. L., Tsiouris, J., Anand, V. K., & Schwartz, T. H. (2011) · Pituitary · doi:10.1007/s11102-011-0350-z · Cited by 135
THERAPY OF ENDOCRINE DISEASE: Treatment of malignant pheochromocytoma and paraganglioma
Baudin, É., Habra, M. A., Deschamps, F., Cote, G. J., Dumont, F., Cabanillas, M. E., Arfi, J., Berdelou, A., Moon, B., Ghuzlan, A. A., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0113 · Cited by 133
Pivonello, R., Petersenn, S., Newell‐Price, J., Findling, J. W., Gu, F., Maldonado, M., Trovato, A., Hughes, G., Salgado, L. R., Lacroix, A., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12431 · Cited by 117
Self-citationGeer, E. B., Shen, W., Strohmayer, E., Post, K. D., & Freda, P. U. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3123 · Cited by 112
Starke, R. M., Reames, D. L., Chen, C.-J., Laws, E. R., & Jane, J. A. (2013) · Neurosurgery · doi:10.1227/neu.0b013e31827b966a · Cited by 113
Barbot, M., Albiger, N. M. E., Ceccato, F., Zilio, M., Frigo, A. C., Denaro, L., Mantero, F., & Scaroni, C. M. (2013) · Pituitary · doi:10.1007/s11102-013-0475-3 · Cited by 121
Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole
Corcuff, J.-B., Young, J., Masquefa-Giraud, P., Chanson, P., Baudin, E., & Tabarin, A. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0913 · Cited by 113
Potential Role for Retinoic Acid in Patients with Cushing's Disease
Pecori Giraldi, F., Ambrogio, A. G., Andrioli, M., Sanguin, F., Karamouzis, I., Corsello, S. M., Scaroni, C., Arvat, E., Pontercorvi, A., & Cavagnini, F. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2328 · Cited by 113
Randomized trial of osilodrostat for the treatment of Cushing disease
Gadelha, M., Bex, M., Feelders, R. A., Heaney, A. P., Auchus, R. J., Gilis-Januszewska, A., Witek, P., Belaya, Z., Yu, Y., Liao, Z., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac178 · Cited by 114
MANAGEMENT OF ENDOCRINE DISEASE: Hyperandrogenism after menopause
Markopoulos, M. C., Kassi, E., Alexandraki, K. I., Mastorakos, G., & Kaltsas, G. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0468 · Cited by 105
Role of stereotactic radiosurgery in the management of pituitary adenomas
Castinetti, F., Régis, J. M., Dufour, H., & Brue, T. C. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.4 · Cited by 116
Dimopoulou, C., Schopohl, J., Rachinger, W., Buchfelder, M., Honegger, J., Reincke, M., & Stalla, G. K. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0634 · Cited by 110
Self-citationKamp, K., Alwani, R. A., Korpershoek, E., Franssen, G. J. H., de Herder, W. W., & Feelders, R. A. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0968 · Cited by 116
Ragnarsson, O., Berglund, P., Eder, D. N., & Johannsson, G. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1945 · Cited by 111
Monaghan, P. J., Owen, L. J., Trainer, P. J., Brabant, G., Keevil, B. G., & Darby, D. (2011) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2011.011014 · Cited by 111
Storr, H. L., Alexandraki, K. I., Martin, L., Isidori, A. M., Kaltsas, G. A., Monson, J. P., Besser, G. M., Matson, M., Evanson, J., Afshar, F., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-1120 · Cited by 110
Self-citationYanase, T., Tajima, T., Katabami, T., Iwasaki, Y., Tanahashi, Y., Sugawara, A., Hasegawa, T., Mune, T., Oki, Y., Nakagawa, Y., et al. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0242 · Cited by 104
Outcomes of pituitary surgery for Cushing’s disease: a systematic review and meta-analysis
Stroud, A., Dhaliwal, P., Alvarado, R., Winder, M. J., Jonker, B., Grayson, J. W., Hamizan, A. K. W., Harvey, R. J., & McCormack, A. I. (2020) · Pituitary · doi:10.1007/s11102-020-01066-8 · Cited by 116
Hameed, N., Yedinak, C. G., Brzana, J., Gultekin, S. H., Coppa, N. D., Dogan, A., Delashaw, J. B., & Fleseriu, M. (2013) · Pituitary · doi:10.1007/s11102-012-0455-z · Cited by 102
“In cases of surgical failure, repeat exploration of the sella represents a controversial treatment option [1, 6, 7, 18, 20, 24, 25].”
BackgroundWagenmakers, M. A. E. M., Netea-Maier, R. T., Prins, J. B., Dekkers, T., den Heijer, M., & Hermus, A. R. M. M. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0308 · Cited by 101
Self-citationFleseriu, M., Pivonello, R., Elenkova, A., Salvatori, R., Auchus, R. J., Feelders, R. A., Geer, E. B., Greenman, Y., Witek, P., Cohen, F., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30313-4 · Cited by 101
Self-citationGuignat, L., & Bertherat, J. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0627 · Cited by 101
Self-citationBroder, M. S., Neary, M. P., Chang, E. Y., Cherepanov, D., & Ludlam, W. H. (2014) · Pituitary · doi:10.1007/s11102-014-0569-6 · Cited by 113
A critical reappraisal of bilateral adrenalectomy for ACTH-dependent Cushing's syndrome
Reincke, M., Ritzel, K., Oßwald, A., Berr, C., Stalla, G. K., Hallfeldt, K. K. J., Reisch, N., Schopohl, J., & Beuschlein, F. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0265 · Cited by 101
Self-citationMedical Treatment of Cushing’s Syndrome: Adrenal-Blocking Drugs and Ketaconazole
Feelders, R. A., Hofland, L. J., & de Herder, W. W. (2010) · Neuroendocrinology · doi:10.1159/000314292 · Cited by 94
“Cushing’s syndrome (CS) is traditionally divided into adrenocorticotropin (ACTH)-dependent CS and ACTH-independent CS. ACTH-dependent CS is usually caused by a corticotropic pituitary adenoma and rarely by ectopic ACTH production by a neuroendocrine tumor. ACTH-independent CS is caused by an adrenal adenoma, adrenal c…”
BackgroundSelf-citationBraun, L., Rubinstein, G., Zopp, S., Vogel, F., Schmid‐Tannwald, C., Escudero, M. P., Honegger, J. B., Ladurner, R., & Reincke, M. (2020) · Endocrine · doi:10.1007/s12020-020-02432-z · Cited by 97
Bertagna, X., & Guignat, L. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3200 · Cited by 92
Self-citationA reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome
Valassi, E., Crespo, I., Gich, I., Rodríguez, J., & Webb, S. M. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04424.x · Cited by 91
Cushing Syndrome: Diagnostic Workup and Imaging Features, With Clinical and Pathologic Correlation
Wagner‐Bartak, N. A., Baiomy, A., Habra, M. A., Mukhi, S. V., Morani, A. C., Korivi, B. R., Waguespack, S. G., & Elsayes, K. M. (2017) · American Journal of Roentgenology · doi:10.2214/ajr.16.17290 · Cited by 108
THERAPY OF ENDOCRINE DISEASE: Steroidogenesis enzyme inhibitors in Cushing's syndrome
Daniel, E., & Newell-Price, J. D. C. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-1014 · Cited by 88
Self-citationWagenmakers, M. A. E. M., Boogaarts, H. D., Roerink, S. H. P. P., Timmers, H. J. L. M., Stikkelbroeck, N. M. M. L., Smit, J. W. A., van Lindert, E. J., Netea-Maier, R. T., Grotenhuis, J. A., & Hermus, A. R. M. M. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0325 · Cited by 89
Self-citationFleseriu, M., Findling, J. W., Koch, C. A., Schlaffer, S.-M., Buchfelder, M., & Gross, C. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1843 · Cited by 86
“Corticotroph tumor progression has been demonstrated after medical treatment (12, 20) and BLA (7, 16, 43).”
BackgroundMethodInfluentialSelf-citationMedical management of Cushing’s disease: what is the future?
Fleseriu, M., & Petersenn, S. (2012) · Pituitary · doi:10.1007/s11102-012-0397-5 · Cited by 88
Self-citationThe USP 8 mutational status may predict long‐term remission in patients with Cushing's disease
Albani, A., Pérez‐Rivas, L. G., Dimopoulou, C., Zopp, S., Colón‐Bolea, P., Roeber, S., Honegger, J., Flitsch, J., Rachinger, W., Buchfelder, M., et al. (2018) · Clinical Endocrinology · doi:10.1111/cen.13802 · Cited by 84
Self-citationAldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism
Amar, L., Plouin, P.-F., & Steichen, O. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-9 · Cited by 83
“PA is easily excluded by the absence of aldosterone hypersecretion in cases of mineralocorticoid hypertension due to an excess secretion of cortisol or deoxycorticosterone[59], of which some can be corrected surgically; in apparent mineralocorticoid excess[60]; during exposure to glycyrrhizic acid (liquorice)[60]; or…”
BackgroundAdvances in the epidemiology, pathogenesis, and management of Cushing’s syndrome complications
Arnaldi, G., Mancini, T., Tirabassi, G., Trementino, L., & Boscaro, M. (2012) · Journal of Endocrinological Investigation · doi:10.1007/bf03345431 · Cited by 93
“The majority of these complications are caused by direct and/or indirect effects of GC excess and, therefore, the primary goal in the prevention and treatment of these complications is correcting that excess (2).”
Self-citationCushing Syndrome: Maybe Not So Uncommon of an Endocrine Disease
Guaraldi, F., & Salvatori, R. (2012) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2012.02.110227 · Cited by 87
“The goals for treatment of patients with CS are reversal of clinical features, normalization of cortisol levels, and long-term control without recurrence.(35) In the presence of ACTH-independent CS caused by an identifiable cortisol-producing adrenal adenoma, the patient should be treated by unilateral adrenalectomy.”
BackgroundPitfalls in the diagnosis and management of Cushing's syndrome
Bansal, V., Asmar, N. E., Selman, W. R., & Arafah, B. M. (2015) · Neurosurgical Focus · doi:10.3171/2014.11.focus14704 · Cited by 81
Carrasco, C. A., Coste, J., Guignat, L., Groussin, L., Dugué, M. A., Gaillard, S., Bertagna, X., & Bertherat, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1171 · Cited by 83
Self-citationDiabetes Mellitus Secondary to Cushing’s Disease
Barbot, M., Ceccato, F., & Scaroni, C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00284 · Cited by 75
“Despite increasing interest in medical therapy, the first-line approach still remains transsphenoidal surgery (26) which provides, when it is performed by an experienced neurosurgeon, a mean remission rate of 77.8% (3, 27).”
BackgroundInfluentialHyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly
Silverstein, J. M. (2016) · Pituitary · doi:10.1007/s11102-016-0734-1 · Cited by 83
An individualized approach to the management of Cushing disease
Fleseriu, M., Varlamov, E. V., Hinojosa‐Amaya, J. M., Langlois, F., & Melmed, S. K. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00868-7 · Cited by 80
Self-citationBelaya, Z. E., Hans, D. B., Rozhinskaya, L. Y., Dragunova, N. V., Sasonova, N. I., Solodovnikov, A. G., Тамерланович, Ц. Т., Dzeranova, L. K., Mel'nichenko, G. A., & Dedov, I. I. (2015) · Archives of Osteoporosis · doi:10.1007/s11657-015-0244-1 · Cited by 81
UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS
Lim, C. T., & Korbonits, M. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0034 · Cited by 86
Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease
Liu, N.-A., Araki, T., Cuevas-Ramos, D., Hong, J., Ben-Shlomo, A., Tone, Y., Tone, M., & Melmed, S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1606 · Cited by 71
Self-citationOutcome of Transsphenoidal Surgery for Cushing Disease: A Single-Center Experience Over 32 Years
Chandler, W. F., Barkan, A. L., Hollon, T. C., Sakharova, A. A., Sack, J. A., Brahma, B., & SCHTEINGART, D. E. (2015) · Neurosurgery · doi:10.1227/neu.0000000000001011 · Cited by 74
“Several other authors have identified a lower recurrence rate associated with an initial low postoperative cortisol level.(4,7,10,11,13,16,21,24) We used a morning cortisol level of 3 mg/dL or less within the first week of surgery as an indication of adrenal insufficiency.”
Influential
Metadata
- Authors
- Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., Klibanski, A., Lacroix, A., Lindsay, J. R., Newell-Price, J., Nieman, L. K., Petersenn, S., Sonino, N., Stalla, G. K., Swearingen, B., Vance, M. L., Wass, J. A. H., & Boscaro, M.
- Affiliations
- Massachusetts General Hospital (US)
- St Bartholomew's Hospital (GB)
- Queen Elizabeth Hospital Birmingham (GB)
- Cedars-Sinai Medical Center (US)
- Hôpital Cochin (FR)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- University of Naples Federico II (IT)
- Radboud University Nijmegen (NL)
- Erasmus MC (NL)
- Centre Hospitalier de l’Université de Montréal (CA)
- Altnagelvin Area Hospital (GB)
- University of Sheffield (GB)
- National Institutes of Health (US)
- University of Duisburg-Essen (DE)
- University of Padua (IT)
- Max Planck Institute of Psychiatry (DE)
- University of Virginia Health System (US)
- Churchill Hospital (GB)
- Marche Polytechnic University (IT)
- Corresponding author
- Boscaro, M.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-07-01
- Volume
- 93
- Issue
- 7
- Pages
- 2454-2462
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3214276
- OpenAlex
- W2147573461
- Cited by
- 853
- References
- 107
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 26 · 2023: 29 · 2022: 40 · 2021: 35 · 2020: 47 · 2019: 59 · 2018: 42 · 2017: 40 · 2016: 44 · 2015: 91 · 2014: 69 · 2013: 74 · 2012: 70
- FWCI
- 38.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Radboud Repository (Radboud University) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Max Planck Institute for Plasma Physics (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- ACTH-dependent Cushing's syndrome, Cushing's disease, ectopic ACTH syndrome, Nelson's syndrome, transsphenoidal surgery, pituitary tumor resection, radiotherapy, medical therapy, bilateral adrenalectomy, remission criteria, consensus statement
- MeSH terms
- ACTH Syndrome, Ectopic, Adrenal Insufficiency, Adrenalectomy, Adrenocorticotropic Hormone, Cushing Syndrome, Humans, Hypophysectomy, Metyrapone, Mitotane, Nelson Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.